Myant Corp., a leader in precision medicine for chronic disease prevention, has announced the acquisition of mmHg Inc., a digital health company specialising in remote blood pressure monitoring, cardiovascular risk management, and chronic disease care. This strategic move extends Myant’s reach into the United States, where mmHg has a strong customer base, including partnerships with major healthcare companies such as A&D Medical.

The acquisition aligns with Myant's broader strategy of "prevention through precision" to drive advancements in personalised, AI-powered remote healthcare.

mmHg Inc.'s platform delivers efficient and consistent care for cardiovascular health, particularly in remote areas. Its software enables healthcare professionals to monitor and analyse blood pressure and other key cardiovascular indicators remotely. By integrating patient data with clinical guidelines, the platform improves the precision of decision-making and supports timely interventions. Esteemed institutions across North America, including Harvard’s Beth Israel Deaconess Medical Center, Johns Hopkins University, Columbia University, NYU, Tulane University, and the University of British Columbia, already utilise the platform to enhance patient care and support clinical research.

The combination of mmHg's digital health capabilities with Myant's expertise in textile computing technology provides healthcare providers with continuous, real-time patient data. This integrated approach is designed to detect health risks earlier, create personalised treatment plans, and improve chronic disease management. The result is expected to be better health outcomes, fewer hospitalisations, and an improved quality of life for patients.

Myant is committed to promoting healthy ageing and transforming digital healthcare to support an ageing population. This acquisition strengthens its ability to offer comprehensive cardiovascular monitoring and risk management solutions.

Integrating mmHg’s software with Myant’s advanced materials enables the development of a connected “second skin” for continuous monitoring. This innovation aims to improve well-being, ensure safety, and provide universal access to healthcare by seamlessly integrating AI into everyday life.

mmHg Inc., co-founded by Dr. Raj Padwal, is a leading provider of remote blood pressure monitoring solutions. The company's clinically validated products are widely used by healthcare providers and researchers in North America to support evidence-based care and research.

This acquisition builds on Myant’s recent expansion into the EU and its commitment to advancing AI-driven solutions, with the appointment of renowned AI scientist Dr. Xin Gao as Chief AI Officer in 2024.

With this move, Myant reinforces its position as a pioneer in precision medicine, combining technology and materials science to enhance patient care and promote longer, healthier lives.




Source: prnewswire.com

Report Abuse